市場調査レポート

世界のプレフィルドシリンジ市場

The Global Pre-filled Syringe Market 2014-2024

発行 GMR Data Ltd 商品コード 317400
出版日 ページ情報 英文 160 Pages, 125 Tables, Charts & Graphs
即納可能
価格
本日の銀行送金レート: 1USD=101.55円で換算しております。
Back to Top
世界のプレフィルドシリンジ市場 The Global Pre-filled Syringe Market 2014-2024
出版日: 2014年10月27日 ページ情報: 英文 160 Pages, 125 Tables, Charts & Graphs
概要

当レポートでは、世界のプレフィルドシリンジ(PFS)市場について調査し、市場成長の促進因子地域・治療セグメント別の分析、主要企業のプロファイル、主要企業3社へのインタビューによる詳細調査、および今後10年間の市場予測などをまとめ、お届けいたします。

第1章 エグゼクティブサマリー

第2章 プレフィルドシリンジのイントロダクション

  • プレフィルドシリンジのイントロダクション
  • プレフィルドシリンジのコンポーネント
  • プレフィルドシリンジの種類
  • プレフィルドシリンジの分類
  • 注入デリバリー装置
  • 針刺しによる怪我の懸念

第3章 世界のプレフィルドシリンジ市場:収益・数量予測

  • 世界市場の概要
  • ガラスプレフィルドシリンジ
  • プラスチックプレフィルドシリンジ

第4章 世界のプレフィルドシリンジ(PFS)市場における主な地域

  • 世界市場の概要
  • 北米のPFS市場
  • 欧州のPFS市場
  • アジア太平洋地域のPFS市場

第5章 プレフィルドシリンジの主な治療セグメント

  • 生物製剤
  • バイオシミラー
  • ワクチン
  • 抗リウマチ剤
  • 抗凝固剤
  • 糖尿病
  • 多発性硬化症(MS)

第6章 SWOT分析

第7章 企業プロファイル

  • Abbott Labs
  • Baxter International
  • Becton Dickinson
  • Schott AG
  • ニプロ
  • Gerresheimer AG
  • West Pharmaceutical Services
  • Ypsomed Holding AG
  • Bespak
  • Unilife Corporation
  • Haselmeier
  • Weigao Group
  • Owen Mumford

第8章 専門家の見解

図表

目次
Product Code: PFS1

The Global Pre-filled Syringe Market 2014-2024 is GMR Data's latest pharma report, covering the pharmaceutical, commercial and strategic developments in the global pre-filled syringe market.

The Global Pre-filled Syringe Market 2014-2024 report analyses how this important sub-sector will continue to grow across the next decade. The report highlights key companies, geographies and products that we believe will deliver double digit growth across the next decade.

Key factors that will drive growth in the pre-filled syringe market include; ease of device administration, improved safety, reduced risk of contamination, elimination of medication errors, low incidence of needlestick injuries, accurate dosing and reduction in medical expenditure due to reduced visits to healthcare facilities.

GMR Data's The Global Pre-filled Syringe Market 2014-2024 report details the prospects for this dynamic pharmaceutical sector with detailed forecasts from 2014-2024. The report will be valuable to those already involved in the PFS market or to those wishing to enter this important market in the future.

The Global Pre-filled Syringe Market 2014-2024 report includes over 125 tables, charts and graphs quantifying and forecasting the market in detail. In addition, the report offers 14 profiles of the leading PFS companies in the market alongside 3 expert interviewees offering key insights into the state of the market currently and in the future;

  • Schott Kaisa
  • West Pharmaceuticals
  • Fresenius Kabi

Table of Contents

1 - Executive Summary

  • 1.1 Global Pre-filled Syringes Market Review
  • 1.2 Chapter Breakdown
  • 1.3 Research and Analysis Methods
  • 1.4 Drivers & Restraints of the Global Pre-Filled Syringe Market 2014-2024
    • 1.4.1 Drivers
      • 1.4.1.1 Growth of the Injectable Drugs Market
      • 1.4.1.2 Success & Growth of Biologics
      • 1.4.1.3 Increased Global Vaccination
      • 1.4.1.4 Increased Drug Self-Administration
      • 1.4.1.5 Technological Advances in the Manufacture of PFS
      • 1.4.1.6 Advances in PFS Technology
    • 1.4.2 Restraints
      • 1.4.2.1 Increased Manufacturing / Distribution Costs
      • 1.4.2.2 Alternative Drug Delivery Methods
      • 1.4.2.3 Controlled Release

2 - Introduction to the Pre Filled Syringe Market

  • 2.1 Introduction to Pre-filled Syringes
    • 2.1.1 What are Pre-Filled Syringes
    • 2.1.2 Market Overview of Pre-filled Syringes
    • 2.1.3 An Increasingly Accessible Sector
    • 2.1.4 Key Advances in the PFS Industry
  • 2.2 Components of Pre-filled Syringes
  • 2.3 Types of Pre-filled Syringes
    • 2.3.1 Glass Syringes
    • 2.3.2 Plastic Syringes
  • 2.4 Classification of Pre-filled Syringes
    • 2.4.1 Single-chamber and Dual-Chamber
    • 2.4.2 Type of needle
  • 2.5 Injection delivery devices
    • 2.5.1 Pen Injectors
    • 2.5.2 Insulin pens
    • 2.5.3 Auto-Injectors
    • 2.5.4 Needle-Free Injectors
    • 2.5.5 Drugs available in Pre-filled Syringes
  • 2.6 Concerns over needle stick Injuries

3 Global Pre-Filled Syringe; Market Revenue and Volume Forecasts to 2024

  • 3.1 Global Market Overview
    • 3.1.1 Global Pre-filled Syringes Market Revenue, 2013-2024
    • 3.1.2 Global Pre-filled Syringes Market Volume, 2013-2024
  • 3.2 Glass Pre-filled syringes
    • 3.2.1 Global Glass Pre-filled Syringes Market Revenue, 2013-2024
    • 3.2.2 Global glass Pre-filled Syringes Market size, 2013 - 2024
  • 3.3 Plastic Pre-filled syringes
    • 3.3.1 Global Plastic Pre-filled Syringes Market Revenue, 2013 - 2024
    • 3.3.2 Global Plastic Pre-filled Syringes Market size, 2013 - 2024

4 - Key Geographies in the Global Pre-Filled Syringe Market 2014-2024

  • 4.1 Global Market Overview
  • 4.2 The North America PFS Market 2013-2024
    • 4.2.1 Key drivers in the North American PFS market
      • 4.2.1.1 Increase in Cancer Treatment
      • 4.2.1.2 Spending on multiple sclerosis (MS)
      • 4.2.1.3 Increase in Diabetes Prevalence
      • 4.2.1.4 Healthcare Expenditure
      • 4.2.1.5 Spend on Vaccination
      • 4.2.1.6 Regulatory Environment for Pre-Filled Syringes
  • 4.3 The Europe PFS Market 2013-2024
    • 4.3.1 Key factors that will drive the PFS market in Europe
      • 4.3.1.1 Favourable reimbursement policies
      • 4.3.1.2 Increased Spend on Healthcare
      • 4.3.1.3 Increase in Europe Wide Diabetic Population
      • 4.3.1.4 Strong contribution to the Biosimilar Market
      • 4.3.1.5 Increase in Cancer Treatment
      • 4.3.1.6 Regulatory Environment
  • 4.4 The Asia Pacific PFS Market 2013-2024
    • 4.4.1 Key drivers of the APAC PFS Market
      • 4.4.1.1 Emerging Middle Classes
      • 4.4.1.2 APAC Diabetes Market
        • 4.4.1.2.1 China Diabetic Market
        • 4.4.1.2.2 India Diabetic Market
        • 4.4.1.2.3 Japanese Diabetic Market
      • 4.4.1.3 Increase in Vaccination demand
        • 4.4.1.3.1 Japanese Vaccination Market
        • 4.4.1.3.2 India Vaccination Market
        • 4.4.1.3.3 China Vaccination Market
      • 4.4.1.4 Growing Cancer Drugs Market across APAC
        • 4.4.1.4.1 Japanese Cancer Drugs Market
      • 4.4.1.5 Increased Biotechnology across APAC
        • 4.4.1.5.1 China Biotechnology
        • 4.4.1.5.2 India Biotechnology
        • 4.4.1.5.3 Japan Biotechnology
    • 4.5 The Rest of the World PFS Market 2013-2024
      • 4.5.1 Key drivers of the ROW PFS market
      • 4.5.1.1 Increased demand for Vaccination
        • 4.5.1.1.1 Russian demand for Vaccination
        • 4.5.1.1.2 Brazil Vaccination Landscape
      • 4.5.1.2 Increasing prevalence of Diabetes
        • 4.5.1.2.1 The Brazilian Diabetes Sector
        • 4.5.1.2.2 The Russia Diabetes Sector
      • 4.5.1.3 Increased Healthcare Spending

5 Leading Therapeutic Segments for Pre-Filled Syringes 2013-2024

  • 5.1 Biologics
    • 5.1.1 Next Generation Biologics
    • 5.1.2 Biologics Pipeline
    • 5.1.3 Key Biologics Exiting Patent
  • 5.2 Biosimilars
    • 5.2.1 Monoclonal Antibodies
    • 5.2.2 Insulin
    • 5.2.3 Erythropoietin
    • 5.2.4 Interferons
    • 5.2.5 G-CSF
    • 5.2.6 Human Growth Hormones
  • 5.3 Vaccines
  • 5.4 Anti-rheumatics
  • 5.5 Anticoagulants
  • 5.6 Diabetes
  • 5.7 Multiple Sclerosis (MS)

6 - SWOT Analysis of the Global Pre-Filled Syringes Market 2014-2024

  • 6.1 Strengths
    • 6.1.1 Ease of use
    • 6.1.2 Accurate Dosage
    • 6.1.3 Reduced Incidence of Needlestick Injuries
    • 6.1.4 Economic advantages
  • 6.2 Weaknesses
    • 6.2.1 Product stability/compatibility issue
    • 6.2.2 Air bubbles during filling
    • 6.2.3 Device Operation issues
    • 6.2.4 Extractable and Leachable contamination
  • 6.3 Opportunities
    • 6.3.1 Increase in the number of self-injecting patients
    • 6.3.2 Growth of Biologics & Biosimilars
    • 6.3.3 Geographic expansion
    • 6.3.4 Vaccination Programmes
    • 6.3.5 Ageing population
  • 6.4 Threats
    • 6.4.1 Alternative Drug Delivery Platforms
    • 6.4.2 Manufacturing complexities
    • 6.4.3 Manufacturer Recalls
    • 6.4.4 Stringent Regulatory Environment

7 Company Profiles

  • 7.1. Abbott Labs
  • 7.2: Baxter International
  • 7.3: Becton Dickinson
  • 7.4: Schott AG
  • 7.5. Nipro Corporation
  • 7.6: Gerresheimer AG
  • 7.7. West Pharmaceutical Services
  • 7.8. Ypsomed Holding AG
  • 7.9: Bespak
  • 7.10: Unilife Corporation
  • 7.11: Haselmeier
  • 7.13: Weigao Group
  • 7.14: Owen Mumford

8 Expert Opinion

  • 8.1 Schott Kaisa
  • 8.2 West Pharmaceuticals
  • 8.3 Fresenius Kabi

Tables

  • Table 1.4: Drivers & Restraints of the Global Pre-Filled Syringe Market 2014-2024
  • Table 1.4.2.2: Total Diabetics & Treatment Statistics US, 2013 (million people)
  • Table 2.2.1: Components of PFS
  • Table 2.2.2: Key components and description of PFS
  • Table 2.4.1.1: Advantages of dual-chamber system
  • Table 2.5.1: Classification of injectors depending upon of the type Use and User
  • Table 2.5.2.1: Different brands of Insulin available in the market
  • Table 2.5.3.1: Benefits of Auto-injector
  • Table 2.5.4.1: Advantages of needle-free
  • Table 2.5.6.1: Categories of drugs where PFS are used:
  • Table 3.1.1.2: Breakdown of Pre-filled Syringes market by region, 2013 ($ bn)
  • Table 3.1.2.1: Pre-filled Syringe Market; Total Revenue, Total Units, Glass Revenue & Plastic Revenue 2013-2024 ($/bn, %)
  • Table 3.1.2.2: Total Revenue, Total Units, Glass & Plastic 2013, 2014, 2019 & 2024 ($/bn, %)
  • Table 4.1.1: Global PFS Market Revenue Forecast 2013-2024 ($/bn, %)
  • Table 4.1.2: Forecast of Regional CAGR 2014-2024 (%)
  • Table 4.1.3; Regional PFS Market Share Breakdown (%)
  • Table 4.1.4: Forecast of Regional Market Share 2014, 2019 & 2024 ($/bn & %)
  • Table 4.1.5: Forecast of Global PFS Revenue & Total Units Shipped 2013-2024 ($/bn & billion units)
  • Table 4.1.6: Regional PFS Unit Sales (billion)
  • Table 4.2.1: The North America PFS Market Forecast 2013-2024 ($/bn & AGR %)
  • Table 4.2.2: The North America PFS Unit Forecast 2013-2024 (billion)
  • Table 4.2.3: Estimated Incidence, Mortality, and Prevalence of Cancer Worldwide and US - 2012
  • Table 4.2.4: Total Diabetics & Treatment Statistics, US, 2013 (million people)
  • 4.2.5: Diabetes population, prevalence and healthcare expenditure in the US and Canada (2013)
  • Table 4.2.6: US Healthcare Spending Per Capita 2000-2013 ($, %)
  • Table 4.3.1: The Europe PFS Market 2013-2024 ($/bn)
  • Table 4.3.2: Forecast of European PFS Unit Sales 2013-2024 (Billion Units)
  • Table 4.3.3 PFS Revenue, by Geography, Europe 2013 ($/ bn / %)
  • Table 4.3.4: EU5 GDP & Healthcare Spending, 2012 ($/bn)
  • Table 4.3.5: Diabetes population, prevalence and healthcare expenditure in Europe - 2013 ($)
  • Table 4.3.6: Estimated Incidence and Mortality rate of Cancer in Europe - 2013
  • Table 4.4.1: Asia-Pacific & Global PFS Market ($/bn & AGR)
  • Table 4.4.2: Forecast of Asia-Pacific PFS Unit Sales 2013-2024 (Billion Units)
  • Table 4.4.3: GDP Growth, India & China 1990-2010 ($/bn, %)
  • Table 4.4.4: Number of Population with Diabetes in China 2008-2030
  • Table 4.4.5: China Diabetes Annual Figures, 2013
  • Table 4.4.6: India Diabetes Annual Figures, 2013
  • Table 4.4.7: Japan Diabetes Annual Figures, 2013
  • Table 4.4.8: Incidence, Mortality, and Prevalence of Cancer Worldwide, China, India & Japan 2012
  • Table 4.4.9: China Pharmaceutical Market for Oncology, 2008 - 2013
  • Table 4.4.10: APAC Biologics & Biosimilars Market Size 2013 ($/bn)
  • Table 4.4.11: Key Biosimilars Approved in India 2014
  • Table 4.4.12: PMDA Approved Biosimilars in Japan 2014
  • Table 4.5.1: The Rest of the World PFS Market 2013-2024 ($/bn, %)
  • Table 4.5.2: Forecast of ROW PFS Unit Sales 2013-2024 (Billion Units)
  • Table 4.5.3; Russian Vaccines Profile 2014
  • Table 4.5.4: Brazilian Vaccines Profile 2014
  • Table 4.5.5: Diabetes population, prevalence and healthcare expenditure in Brazil, 2013
  • Table 4.5.6: Diabetes population, prevalence and healthcare expenditure in Russian, 2013
  • Table 4.5.7: GDP Growth Brazil & Russia 2000-2010 ($/bn)
  • Table 4.5.8: Russia & Brazil GDP & Healthcare Spend 2000, 2005 & 2010 ($/bn)
  • Table 5.1.1: Global Biologics Market Size by Region, 2013 ($/bn)
  • Table 5.1.2: Biologic medicines under development-by therapeutic category 2014
  • Table 5.1.3: Biologic medicines under development-by product category 2014
  • Table 5.1.4: Expiry dates for major patents on best-selling biological products 2011-2024
  • Table 5.1.5: Key products potential targeted by biosimilar developers post patent expirations
  • Table 5.2.1: Global Biosimilars Market Size by Region, 2013 ($/bn)
  • Table 5.2.2: Key Drivers of the Global Biosimilar Market
  • Table 5.2.3: Key Restraints in the Global Biosimilar Market 2014
  • Table 5.2.4: Biologics, which lose patent and the opportunity for Biosimilars 2013 ($/bn)
  • Table 5.2.5: Biologics under different phases of trials
  • Table 5.3.1: Vaccine manufacturers' classification for supply
  • Table 5.3.2: Top 10 best-selling vaccine, manufacturer and application 2013
  • Table 5.5.3: Global Anticoagulants market by region, 2013 ($/bn, %)
  • Table 5.6.1: Top 10 selling diabetes drugs, 2013
  • Table 6.1: SWOT Analysis of the Global Pre-filled Syringes Market 2014-2024
  • Table 6.3.1: Diabetes in the US, Diagnosed, Undiagnosed and New Cases 2012
  • Table 6.3.2: BRIC Population, Healthcare Expenditure per Capita 2006 / 2012 ($/p/a)
  • Table 7.1.1: Abbott Labs Key PFS/BGMS Products, 2014
  • Table 7.2.1: Baxter International Key PFS Products, 2014
  • Table 7.3.1: Key Becton Dickinson PFS / IV Products, 2014
  • Table 7.4.1: Schott Key PFS/Needle Products, 2014
  • Table 7.5.1: Nipro Corporation Key PFS / Related Products, 2014
  • Table 7.6.1: Gerresheimer Key PFS / Syringe Products, 2014
  • Table 7.7.1: West Pharmaceutical Key Products, 2014
  • Table 7.8.1: Ypsomed Key PFS/Injection Products, 2014
  • Table 7.9.1: Bespak Key PFS / Syringe Products, 2014
  • Table 8.10.1: Unilife Corporation Key PFS/Injection Products, 2014
  • Table 7.11.1: Haselmeier Key PFS / Injection Products 2014
  • Table 7.13.1: Weigao Group Key PFS / Syringe Products, 2014
  • Table 7.14.1: Owen Mumford Key PFS / Syringe Products, 2014

List of Figures

  • Figure 2.6.1: Breakdown of Risk of Needlestick Injury 2014
  • Figure 3.1.1.1: Forecast of the Global Pre-filled Syringes Market, 2013-2024 ($/bn)
  • Figure 3.1.1.2: Breakdown of Pre-filled Syringes market by region, 2013 ($/bn)
  • Figure 3.1.2.1: Forecast of the Global Pre-filled Syringes Market, 2013-2024 (bn units)
  • Figure 3.2.1.1: Forecast of the Global Glass Pre-filled Syringes Market, 2013-2024 ($/bn)
  • Figure 3.2.2.1: Forecast of the Global Glass Pre-filled Syringes Market, 2013-2024 (bn units)
  • Figure 3.3.1.1: Forecast of the Global Plastic Pre-filled Syringes Market, 2013-2024 ($/bn)
  • Figure 3.3.2.1: Forecast of the Global Plastic Pre-filled Syringes Market, 2013-2024 (bn units)
  • Figure 4.1.1: Global PFS Market Revenue Forecast 2013-2024 ($/bn, %)
  • Figure 4.1.2 Percentage Share of the Global PFS Market, 2014 (%)
  • Figure 4.1.3 Percentage Share of the Global PFS Market, 2019 (%)
  • Figure 4.1.4 Percentage Share of the Global PFS Market, 2024 (%)
  • Figure 4.2.1 PFS Unit sales, US, (billions) 2013-2024
  • Figure 4.2.2 US Healthcare Spending Per Capita 2000-2013 ($)
  • Figure 4.3.1 PFS Unit sales, Europe, (billions) 2013-2024
  • Figure 4.3.2 PFS Market Revenue, by Geography, Europe, 2013 (%)
  • Figure 4.3.3: EU5 GDP & Healthcare Spending, 2012 ($/bn)
  • Figure 4.3.4 China Per Capita Disposable Income 2005-2013 ($)
  • Figure 4.4.1 PFS Unit sales, ROW, (billions) 2013-2024
  • Figure 4.4.2 Russia & Brazil Healthcare Spend 2000, 2005 & 2010 ($/bn)
  • Figure 5.1.1: Global Biologics Market Forecast, 2013-2024 ($/bn)
  • Figure 5.1.2: Global Biologics Market Size by Region, 2013 ($/bn)
  • Figure 5.2.1: Global Biosimilar Market Forecast, 2013-2024 ($/bn)
  • Figure 5.2.2: Global Biosimilar Market Size by Region, 2013 ($/bn)
  • Figure 5.3.1: Global Vaccine Market Forecast, 2013-2024 ($/bn)
  • Figure 5.4.1: Global Anti-rheumatics Market Forecast, 2013-2024 ($/bn)
  • Figure 5.4.2: Market Share of Key Players in Anti-rheumatics Market, 2013 (%)
  • Figure 5.4.3: Market Share of Key Brands in Anti-rheumatics Market, 2013 (%)
  • Figure 5.5.1: Global Anticoagulants Market Forecast, 2013-2024 ($/bn)
  • Figure 5.5.2: Global Anticoagulants Market, by region, 2013 (%)
  • Figure 5.6.1: Global Anti-diabetic Drugs Market Forecast, 2013-2024 ($/bn)
  • Figure 5.7.1: Breakdown of Multiple Sclerosis Market, by Region; 2013, ($/bn)
  • Figure 5.7.2: Forecast of the Global Multiple Sclerosis Market, 2013-2024 ($/bn)
  • Figure 5.7.3: Top 5 MS Brands, Market Share, 2013
  • Figure 8.1.1: Abbotts Regional Sales Breakdown, 2013
  • Figure 8.2.1: Baxter Regional Revenue Breakdown 2013
  • Figure 8.4.1: Schott's Net Sales, by Region, 2013
  • Figure 8.5.1: Nipro Regional Net Sale Breakdown, 2013-2014
  • Figure 8.6.1: Gerresheimer AG Regional Net Sales, 2013-14
  • Figure 8.7.1: West Pharmaceutical Regional Net Sales, 2013-14
Back to Top